Drugs / Magnesium iron hydroxycarbonate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00841126 | Jul 2009 → Jul 2011 | chronic renal failure syndrome | Ineos Healthcare Limited | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Magnesium iron hydroxycarbonate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00841126 ↗ |
| Known as | Alpharen, magnesium iron hydroxycarbonate | “Alpharen, magnesium iron hydroxycarbonate” NCT00841126 ↗ |
| Route | Oral | “500 mg tablets, administered orally” NCT00841126 ↗ |